Though the recent wave of merger-mania among biotech stocks still looks like it’s in its final chapters, it’s not like we’re never going to see another buyout from the industry again. They’re just going to be fewer and farther between until valuations come down a bit.
So, which biotech stocks remain the market’s most likely acquisition candidates? Here are five takeover targets speculators may still find worth a shot … not just because they’re possible M&A plays, but because they have compelling pipelines even if they never get bought up by bigger biotech companies.
Here are the top five biotech stocks that are also buyout candidates.